These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7517251)

  • 41. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
    Pradier O; Hille A; Schmiberger H; Hess CF
    Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus.
    Tsuchiya Y; Onda M; Miyashita M; Sasajima K
    Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
    Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CYFRA 21-1. A new marker in lung cancer.
    Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A
    Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
    Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
    Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E
    Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
    Takada M; Masuda N; Matsuura E; Kusunoki Y; Matui K; Nakagawa K; Yana T; Tuyuguchi I; Oohata I; Fukuoka M
    Br J Cancer; 1995 Jan; 71(1):160-5. PubMed ID: 7529525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
    Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
    J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck.
    Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J
    Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
    Nisman B; Biran H; Heching N; Barak V; Ramu N; Nemirovsky I; Peretz T
    Br J Cancer; 2008 Jan; 98(1):77-9. PubMed ID: 18087272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
    Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
    Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
    Dis Esophagus; 2017 Nov; 11(1):35-39. PubMed ID: 29040480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
    Okada M; Sakamoto T; Yuki T; Mimura T; Nitanda H; Miyoshi K; Tsubota N
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):825-30. PubMed ID: 15821650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.